Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul-Aug;71(4):276-281.
Epub 2018 Aug 28.

Identifying Drug Interactions between Enzalutamide and Complementary Alternative Medications in a Patient with Metastatic Prostate Cancer: A Case Report

Thomas Brownlee  1 , Colleen Olson  2 , Michelle Deschamps  3
Affiliations

Identifying Drug Interactions between Enzalutamide and Complementary Alternative Medications in a Patient with Metastatic Prostate Cancer: A Case Report

Thomas Brownlee et al. Can J Hosp Pharm. 2018 Jul-Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Michelle Deschamps has received personal fees from Novartis and Gilead for service on various advisory boards, unrelated to this case report. No other competing interests were declared.

Similar articles

References

    1. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, et al. Role of testosterone in managing advanced prostate cancer. Urology. 2012;80(4):754–62. doi: 10.1016/j.urology.2012.05.006. - DOI - PubMed
    1. von Klot CA, Kuczyk MA, Boeker A, Reuter C, Imkamp F, Herrmann TRW, et al. Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. Oncol Lett. 2017;13(1):22–8. doi: 10.3892/ol.2016.5392. - DOI - PMC - PubMed
    1. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–63. doi: 10.1016/S1470-2045(15)00518-5. - DOI - PubMed
    1. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34(18):2098–106. doi: 10.1200/JCO.2015.64.9285. - DOI - PubMed
    1. Lexicomp Online®, Lexi-Drugs Online® [online database] Hudson (OH): Wolters Kluwer Clinical Drug Information, Inc; Enzalutamide. [cited 2017 Jul 26]. Accessed through institutional subscription. Subscription required to access content.

LinkOut - more resources